Advertisement
Australia markets closed
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • AUD/USD

    0.6501
    +0.0012 (+0.18%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.77
    -0.59 (-0.71%)
     
  • GOLD

    2,328.60
    -13.50 (-0.58%)
     
  • Bitcoin AUD

    102,209.64
    +263.15 (+0.26%)
     
  • CMC Crypto 200

    1,432.40
    +8.30 (+0.58%)
     

Analyzing Valeant’s Quarterly Earnings and Estimates

Analyzing Valeant’s Quarterly Earnings and Estimates

Valeant Pharmaceuticals (VRX) reported a GAAP net loss of ~$2.7 billion during the first quarter—compared to the GAAP net income of ~$628 million during the first quarter of 2017. Also, the GAAP EPS was negative at -$7.68. The company reported a loss during the first quarter—compared to the GAAP EPS of $1.79 during the first quarter of 2017.